Insulet is engaged in the development, manufacturing and sale of its Omnipod? System, an insulin delivery system for people with insulin-dependent diabetes, which consists of two product lines: the Omnipod Insulin Management System and Omnipod DASH? Insulin Management System. The Omnipod System features a self-adhesive disposable tubeless Pod, which is worn on the body and provides up to three days of non-stop insulin delivery without the need to see or handle a needle, and a handheld Personal Diabetes Manager. The Omnipod System communicates wirelessly, provides for automated cannula insertion and eliminates the need for multiple daily injection therapy or the use of pump and tubing.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.